Ru(II)-Based Amino Acid Complexes Show Promise for Leukemia Treatment: Cytotoxicity and Some Light on their Mechanism of Action
Ruthenium is attracting considerable interest as the basis for new compounds to treat diseases, and studies have shown that complexes with different structures have significant antineoplastic and antimetastatic potential against several types of tumors, including tumors resistant to cisplatin drugs. We examined the cytotoxic, genotoxic, and pro-apoptotic activities of six ruthenium complexes containing amino acid with general formulation [Ru(AA)(bipy)(dppb)]PF6, where AA = amino acid (alanine, glycine, leucine, lysine, methionine, or tryptophan); bipy = 2,2´-bipyridine; and dppb = [1,4-bis(diphenylphosphine)butane], against A549 (lung carcinoma) and K562 (chronic myelogenous leukemia) cancer cells. The results show that the ruthenium complexes tested were able to induce cytotoxicity in A549 and K562 cancer cells. Complex 1 containing alanine inhibited the cell viability of A549 and K562 tumor cells by inducing apoptosis, as evidenced by an increased number of Annexin V-positive cells and the induction of DNA damage and cell cycle arrest. Complex 1 was able to induce caspase-mediated apoptosis in K562 cells through the mitochondrial dysfunction, the upregulation of apoptotic genes, and the downregulation of Bcl2 anti-apoptotic gene. Besides being cytotoxic to K562 and A549 cells, ruthenium complex containing alanine shows low cytotoxicity and genotoxicity against non-tumor cells. These results suggest that the ruthenium (II) complex is a potential safe and efficient antineoplastic candidate for leukemia treatment.
KeywordsLeukemia Mitochondria dysfunction DNA damage Apoptosis
This study was funded by Brazilian research financing institutions: Foundation for Research Support of the State of Maranhão (FAPEMA) [grant number PPP-02100/14], and Brazilian National Counsel of Technological and Scientific Development (CNPq) (grant number 454266/2014-6 and 31960/2008-3).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest or no financial conflict of interest to disclose. The authors Aliny Pereira de Lima, Márcio Aurélio Pinheiro Almeida, Francyelli Mello-Andrade, Alzir Azevedo Batista, and Elisângela de Paula Silveira-Lacerda report have a national patent application filing (number patent BR1020130336041A2).
- 4.Riddell IA, Lippard SJ (2018) Cisplatin and oxaliplatin: our current understanding of their actions. In: Sigel A, Sigel H, Freisinger E, Sigel RKO (eds.) Metallo-Drugs: Development and Action of Anticancer Agents, Berlin, Boston: De Gruyter, pp 1–42. https://doi.org/10.1515/9783110470734-007 Google Scholar
- 9.Lima AP, Pereira FC, Almeida MAP, Mello FMS, Pires WC, Pinto TM, Delella FK, Felisbino SL, Moreno V, Batista AA, Silveira-Lacerda EP (2014) Cytotoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells. PLoS One 9:e105865. https://doi.org/10.1371/journal.pone.0105865 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Porto HKP, Vilanova-Costa CAST, Mello FMS, Costa WL, Lima AP, Pereira FC, Almeida MAP, Graminha AE, Batista AA, Silveira-Lacerda EP (2015) Synthesis of a Ru(II) tryptophan-associated complex and biological evaluation against Ehrlich murine breast carcinoma. Transit Met Chem 40:1–10. https://doi.org/10.1007/s11243-014-9882-1 CrossRefGoogle Scholar
- 12.Mello-Andrade F, da CostaWL PWC, Pereira FC, Cardoso CG, Lino-Junior RS, Irusta VRC, Carneiro CC, de Melo-Reis PR, Castro CH, Almeida MAP, Batista AA, Silveira-Lacerda EP (2017) Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression. Tumour Biol 39(10):1010428317695933. https://doi.org/10.1177/1010428317695933 CrossRefPubMedGoogle Scholar
- 13.Mello-Andrade F, Cardoso CG, Silva CR, Chen-Chen L, Melo-Reis PR, Lima AP, Oliveira R, Ferraz IBM, Grisolia CK, Almeida MAP, Batista AA, Silveira-Lacerda EP (2018) Acute toxic effects of ruthenium (II)/amino acid/diphosphine complexes on Swiss mice and zebrafish embryos. Biomed Pharmacother 107:1082–1092. https://doi.org/10.1016/j.biopha.2018.08.051 CrossRefPubMedGoogle Scholar
- 17.Lima AP, Pereira FC, Vilanova-Costa CA, Soares JR, Pereira LC, Porto HK, Pavanin LA, Santos WB, Silveira-Lacerda EP (2012) Induction of cell cycle arrest and apoptosis by ruthenium complex cis-(dichloro)tetramineruthenium(III) chloride in human lung carcinoma cells A549. Biol Trace Elem Res 147:8–15. https://doi.org/. https://doi.org/10.1007/s12011-011-9275-7 CrossRefPubMedGoogle Scholar
- 20.Liu SH, Zhu JW, Xu HH, Wang Y, Liu YM, Liang JB, Zhang GQ, Cao DH, Lin YY, Wu Y, Guo QF (2016) Protein-binding, cytotoxicity in vitro and cell cycle arrest of ruthenium(II) polypyridyl complexes. Spectrochim Acta A Mol Biomol Spectrosc 161:77–82. https://doi.org/10.1016/j.saa.2016.02.036 CrossRefPubMedGoogle Scholar
- 21.Zhang C, Han BJ, Zeng CC, Lai SH, Li W, Tang B, Wan D, Jiang GD, Liu YJ (2016) Synthesis, characterization, in vitro cytotoxicity and anticancer effects of ruthenium(II) complexes on BEL-7402 cells. J Inorg Biochem 157:62–72. https://doi.org/. https://doi.org/10.1016/j.jinorgbio.2016.01.003 CrossRefPubMedGoogle Scholar
- 22.Magalhães LF, Mello-Andrade F, Pires WC, Silva HD, da Silva PFF, Macedo LM, de Castro CH, Carneiro CC, Cardoso CG, de Melo Reis PR, Oliveira LC, Caetano RR, Batista AA, Silveira-Lacerda EP (2017) cis-[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cell. Chem Biol Interact 278:101–113. https://doi.org/10.1016/j.cbi.2017.09.013 CrossRefPubMedGoogle Scholar
- 23.Pires WC, Lima BAV, de Castro PF, Lima AP, Mello-Andrade F, Silva HD, da Silva MM, Colina-Vegas L, Ellena J, Batista AA, Silveira-Lacerda EP (2018) Ru(II)/diphenylphosphine/pyridine-6-thiolate complexes induce S-180 cell apoptosis through intrinsic mitochondrial pathway involving inhibition of Bcl-2 and p53/Bax activation. Mol Cell Biochem 438:199–217. https://doi.org/10.1007/s11010-017-3129-3 CrossRefPubMedGoogle Scholar
- 24.Velozo-Sá VS, Pereira LR, Lima AP, Mello-Andrade F, Rezende MRM, Goveia RM, Pires WC, Silva MM, Oliveira KM, Ferreira AG, Ellena J, Deflon VM, Grisolia CK, Batista AA, Silveira-Lacerda EP (2019) In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(II)/2-mercaptopyrimidine complexes. Dalton Trans 48:6026–6039. https://doi.org/doi. https://doi.org/10.1039/c8dt03738h CrossRefPubMedGoogle Scholar
- 27.Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, el-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nuñez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on cell death 2012. Cell Death Differ 19:107–120. https://doi.org/. https://doi.org/10.1038/cdd.2011.96 CrossRefPubMedGoogle Scholar
- 32.Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW (2009) Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15:1645–1654. https://doi.org/10.1158/1078-0432.CCR-08-2581 CrossRefPubMedPubMedCentralGoogle Scholar